DNA RNA and Cells

11 May 2015

RXi Pharmaceuticals Presented Promising New Data with Self-delivering RNAi Compounds Targeting Tyrosinase and Collagenase

11 May 2015

Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma

7 May 2015

Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases

6 May 2015

Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates with DsiRNA-EX Conjugates Being Investigated for Treatment of Primary Hyperoxaluria Type 1 (PH1)

5 May 2015

TxCell presents positive results for Col-Treg in a model of autoimmune uveitis at 2015 ARVO Annual Meeting, Denver, Colorado, US

5 May 2015

ZIOPHARM Announces Initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy in Patients With Brain Cancer

5 May 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT

4 May 2015

Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision

30 April 2015

NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

27 April 2015

BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

27 April 2015

ZIOPHARM Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With Locally Advanced or Metastatic Breast Cancer

27 April 2015

Celladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure

27 April 2015

Late-Breaking Oral Presentation at The International Liver Congress™ (ILC 2015) Highlights RG-101’s Potent, Durable and Pan-Genotypic Effects in Diverse HCV Population

23 April 2015

Dimension Therapeutics to Develop Gene Therapy Treatments for Patients with Ornithine Transcarbamylase (OTC) Deficiency and Glycogen Storage Disease Type Ia (GSDIa)

23 April 2015

AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform

23 April 2015

Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis

22 April 2015

Mirna Therapeutics Presents Interim Phase 1 Data on First-in-Class, First-in-Clinic microRNA-34 Mimic, MRX34, at the 2015 Annual Meeting of the American Association for Cancer Research

22 April 2015

Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia

17 April 2015

Athersys Announces Results From Phase 2 Study of MultiStem(R) Cell Therapy for Treatment of Ischemic Stroke

17 April 2015

Transgene SA: Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer

16 April 2015

Isarna Initiates First-in-Human Phase I Trial for ISTH0036 to Treat Advanced Glaucoma

16 April 2015

PsiOxus Therapeutics Expands Clinical Studies for Immuno-Oncolytic Treatment Following Positive Response to Intravenous Delivery

14 April 2015

Cardio3 BioSciences Enrolls First Patient in Phase I Trial for NKG2D CAR T-Cell

13 April 2015

Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

13 April 2015

First Duchenne Muscular Dystrophy Patient Treated in Follistatin Gene Therapy Trial

13 April 2015

Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520

10 April 2015

Dicerna Presents New β-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory

8 April 2015

Lion Biotechnologies Announces Publication of Data From Clinical Study of Metastatic Cervical Cancer Patients Treated With HPV-TIL

8 April 2015

RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Selected as Clinical Candidate by AstraZeneca

7 April 2015

International Stem Cell Corporation Demonstrates Reversal of Neurological Stroke Symptoms Using Neural Stem Cells

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD40 Agonists & CD40/L Antagonists Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Her3-Targeted Immunotherapy Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Report Package: Bispecific Antibodies

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics